Actinium Pharmaceuticals Inc (NYSE MKT:ATNM), a biopharmaceutical Company developing innovative targeted payload immunotherapeutics for the treatment of advanced cancers, announced that the presentation of poster and abstract at ASCO 2015, the 51st Annual Meeting of American Society of Clinical Oncology, was given in Chicago on May 31. Data from the Company’s ongoing multi-center Phase 1/2 Study for Actimab-A for the treatment of newly diagnosed Acute Myeloid Leukemia (AML) in elderly patients were presented by Dr. Joseph Jurcic of Columbia University Medical Center, Actinium’s Clinical Advisory Board Chairman. Among the first 12 patients treated at increasing dose levels, two Actimab-A treated patients achieved complete remission with different degrees of hematological recovery (CRi) and one patient achieved complete remission with incomplete platelet count recovery (CRp), for a combined overall response rate of 25% among all patients and 67% among patients treated at the highest dose level to date. Patients ranged from 68 to 87 years of age, all with high- or intermediate-risk cytogenetics; half of them had prior MDS therapy. Dose limiting toxicities were limited to one patient with prolonged myelosuppression. No extramedullary dose limiting toxicities were observed. Patients had high pre-treatment leukemia burdens of up to 88% in the bone marrow, and half had blast reductions >50% after Actimab-A treatment.
The Company also recently began the fourth and last cohort (2.0 μCi/kg per dose) in the Phase I portion of this trial. “These results generated significant interest and were well received by the oncology experts,” said Dr. Joseph Jurcic, the presenter and lead author of the poster and abstract. “Oncologists were particularly excited to see objective responses in patients who already received best available therapy for their prior blood cancer.” Summary of the presented data can be found in the ASCO Abstract #7050 titled “Phase I trial of α- particle therapy with actinium-225 (225Ac)-lintuzumab (anti-CD33) and low-dose cytarabine (LDAC) in older patients with untreated acute myeloid leukemia (AML).” Dr. Jurcic is Director of the Hematologic Malignancies Section of the Hematology/Oncology Division and Professor of Clinical Medicine at Columbia University Medical Center. He is a hematologist/oncologist focusing on the treatment of acute and chronic leukemias, myeloproliferative neoplasms, and myelodysplastic syndrome. His research interests include acute myeloid leukemia, radioimmunotherapy with alpha and beta particle-emitting radioisotopes, monoclonal antibody therapy for leukemia, development of novel small molecule inhibitors for leukemia and molecular monitoring of minimal residual disease. He is the primary investigator for the current Actimab-A clinical trial and Clinical Advisory Board Chairman. He received his medical degree from the University of Pennsylvania and completed his fellowship in Hematology-Oncology at Memorial Sloan-Kettering Cancer Center. (Original Source)
Shares of Actinium Pharmaceuticals closed yesterday at $2.99 . ATNM has a 1-year high of $12.75 and a 1-year low of $2.31. The stock’s 50-day moving average is $2.89 and its 200-day moving average is $4.06.
On the ratings front, MLV & Co. analyst Arlinda Lee reiterated a Buy rating on ATNM, with a price target of $15, in a report issued on March 17. The current price target represents a potential upside of 401.7% from where the stock is currently trading.
According to TipRanks.com, Lee has a total average return of 4.8%, a 57.4% success rate, and is ranked #1273 out of 3610 analysts.
Actinium Pharmaceuticals Inc is a biopharmaceutical company which develops drugs for treatment of cancer. It is a development stage company.